Prognosis
Hopes Are Rising for a Homegrown mRNA Vaccine in China
- Walvax’s mRNA vaccine gets go-ahead for booster study
- Walvax approval as a booster could curb need for BioNTech shot
Source: Feature China/Barcroft Media
This article is for subscribers only.
China appears to be accelerating the development of its first homegrown mRNA Covid-19 vaccine, as Beijing’s authorization of the Pfizer Inc.-BioNTech SE shot remains in limbo.
The vaccine from Walvax Biotechnology Co. and Suzhou Abogen Biosciences Co. will be tested as booster shot in fully immunized adults as part of the pivotal trials that are already underway. The approach could give the companies a potential fast-track to the market in the world’s most populous country before those trials are fully completed.